The firm postponed the launch to enhance Omni's capabilities, in the meantime focusing on opportunities in near-patient testing for its GeneXpert system.
The test was developed by Quest's Focus Diagnostics subsidiary and is the first from a commercial lab to receive an EUA.
Total revenues were $144.8 million, a 13 percent increase on a constant currency basis, and beating the average analysts' estimate of $140.2 million.
The UK-based firm plans to marry its core strengths with the probes and PCR platforms, and to build its sales force in the US.
Infectious disease product revenues fell 25 percent year over year, while women's health and gastrointestinal sales were flat.
In Science this week: role for RNA splicing in genetic variation, and more.
An advocacy group sues the US Food and Drug Administration over redactions of information about advisory committee members, Stat News reports.
Mexico is trying to lure young genomics researchers back home with their own labs, Science reports.
A molecular autopsy has aided a woman's search for why sudden cardiac death has stalked her family, the Wall Street Journal reports.